6th - 7th December 2018, Boston, USA
This year’s event will bring together the pioneers supercharging immunotherapy and vaccine development to share key clinical data and insights from sample acquisition, all the way through to vaccine manufacturing and getting a product to market.
Hear the latest clinical updates from pioneers in this field and define your commercialization roadmap to achieve future regulatory success, scale manufacturing and ensure enhanced clinical efficacy.
Increasing the number of patients that respond successfully to cancer immunotherapies is the next big step in the fight against cancer. Recent studies have shown that the more tumor-specific mutations, or neoantigens, the cancer cells have, the greater the chance that the tumor will not be tolerated by the immune system. With increasing access to next generation sequencing (NGS) technologies, cancer researchers are scouring the tumor genome, including the mutanome, to find new therapies.
At the Neoantigen 2018, receive clinical updates on current programs, regulations for individualized products and scaling down manufacture for personalized therapeutics.
The BioTech Pharma Summit: Neoantigen 2018 is the dedicated end-to-end industry focused meeting ensuring the supercharging of immunotherapies and cancer vaccines to bring truly individualized therapies to patients in need. Join us as the industry seeks to demonstrate significant clinical proof of concept and ensure you and the key stakeholders can make the scientific, clinical and commercial decisions needed to bring these therapies market.
More details at: https://biotechpharmasummit.com/index.php/event/neoantigen-2018/